Theranos trial puts investors in the spotlight

Read online | Don't want to receive these emails? Manage your subscription.

PitchBook

Log in

The Weekend Pitch

September 12, 2021

Presented by Stout

Theranos founder Elizabeth Holmes (Ethan Swope/Getty Images)

Silicon Valley's go-go venture capital system has gone on trial in a packed, fifth-floor courtroom in downtown San Jose.

In federal court, lawyers for the US government have begun pressing fraud charges against Elizabeth Holmes, founder of Theranos, the failed blood-test startup that for many symbolizes the danger of funding bold dreams without proper due diligence and board oversight.

I'm Alexander Davis, and this is The Weekend Pitch. Contact me at alec.davis@pitchbook.com or @alecdavis.

Theranos trial puts Silicon Valley investors in the spotlight: Where are they now?

Opening arguments in the Holmes trial, which is expected to last at least a few months, suggest that much of the evidence will center on the risk investors agreed to take and whether Holmes fooled them into enabling a scandal of historic significance. Theranos dissolved in 2018, the same year Holmes and her former business and romantic partner Sunny Balwani were indicted.

Prosecutors say Holmes hoodwinked investors into funding her failing technology with an estimated $800 million-plus. Her lawyer responded in court that she didn't set out to deceive people—rather that she mistakenly believed the testing device would succeed, and that her "failure is not a crime."

Whether Holmes is guilty will be up to a jury of five women and seven men. Part of their deliberations will be about how transparent Holmes was in financial projections and on the struggles of its signature device, Edison. Balwani will be tried separately later on.

The list of potential witnesses in the Holmes case numbers more than 200 people, including famous Theranos backers like Henry Kissinger, Rupert Murdoch and James Mattis.

While Holmes is the current target of the prosecution, the trial figures to shine a light on the people who piled onto the Theranos cap table and cheered on Holmes. Their vantage points and their ability to understand the risks of their bets will be picked apart.

So where are those investors now? And what strategy or funding style have they deployed in the aftermath of the Theranos scandal?

Quote/Unquote

(krisanapong detraphiphat/Getty Images)

"Over the last three years, there has been a change in investor focus away from 'Can we make money on this asset?' to 'Is this asset also creating social value in the world?'"

—Jason Lee, co-founder and CEO of DailyPay, a provider of on-demand cash services that lets workers access their wages in real time.

With its excessive interest rates and debt traps, traditional payday lending has been widely criticized as predatory. But in recent years, new fintech startups have arrived on the scene, challenging payday lenders with their earned wage access products and ESG agendas. In an effort to position themselves as socially responsible investors, many venture capitalists are taking the bait.

Deal Flow

SoftBank's Vision Funds have seen an increasing number of exits in recent quarters. The first vehicle, which is now nearly five years old and has a fund life of 12 to 14 years, is no exception. While that still leaves plenty of time for the firm to further cultivate its gains, it will also need to shift its focus to managing its portfolio of public companies.

PitchBook has created a proprietary index that assesses the post-IPO record of SoftBank's portfolio companies. The Vision Funds' US-listed public holdings have performed well on a market cap-weighted basis. However, a small number of its investments are responsible for driving that growth, including 10X Genomics, Guardant Health and Vir.

How are the Japanese conglomerate's other publicly traded companies faring? Find out in our recent analyst note.

Did you know ...

(Eoneren/Getty Images)

... That in 2016, when the term "femtech" was coined, global annual VC funding for such startups barely cracked $500 million?

Capital investment for femtech startups has now crossed the $1 billion mark for the first time, according to PitchBook data.

Several factors have propelled new growth opportunities in the space, including increased representation of women in the VC industry, rising awareness and acceptance of women's health issues, and continued success of the direct-to-consumer model.

Datapoints

From a favorable risk-reward spectrum to lucrative pre-IPO rounds, venture returns have become highly appealing to non-venture investors.

Private equity firms are participating in more than half of all US venture capital deals by value, up from 36.9% just two years ago, according to PitchBook data.

Growth-focused firms Insight Partners, General Atlantic and OrbiMed are among the most active leaders in the race to grab a piece of tomorrow's public companies.

To learn more about how the world of venture capital has become increasingly attractive to private equity, hedge funds and other nontraditional investors, check out these five charts.

Recommended reads

Though many restaurants have reopened with the easing of pandemic restrictions, many are still struggling to hire staff. Meet six people in the Bay Area who decided to quit the industry for good. [San Francisco Chronicle]

A look at how Pinterest is using new tech to fight racist algorithms. [Fast Company]

Eight leaders from firms like Bain Capital, Thoma Bravo and The Carlyle Group on what successful private equity shops have in common. [Institutional Investor]

Employers may view remote work as a way to save money by cutting pay, but some employees argue that their work has the same value no matter where they're doing it. [The Wall Street Journal]

As sports betting becomes increasingly legal in the US, more Americans are betting more money than ever. But it may be the local bookies who have the advantage this NFL season. [Forbes]

How one Australian startup is beating China in the race to make solar panels cheaper and more efficient. [Bloomberg]

This edition of The Weekend Pitch was written by Alexander Davis and Priyamvada Mathur. It was edited by Andrew Woodman, Angela Sams and Sam Steele.

Were you forwarded The Weekend Pitch? Sign up at pitchbook.com/subscribe.

Since yesterday, the PitchBook Platform added:

60

People

21

Companies

See what our data software can do

About PitchBook | Terms of use | Advertise with us | Contact

This email was sent to you via the PitchBook Platform.

Do you want to change your email address, get a different edition or unsubscribe? Manage your subscription here.

Earned wage startups public portfolio companies The Weekend Pitch venture capital system packed fifthfloor courtroom downtown San Jose proper due diligence femtech funding frenzy Silicon Valley investors

Theranos trial puts investors in the spotlight

Theranos trial puts Silicon Valley investors in the spotlight: Where are they now?

Quote/Unquote

Deal Flow

Did you know ...

Datapoints

Recommended reads

Key phrases

Older messages

Does style impact performance?

Private funds battle back

Flo adds to femtech frenzy

Charting PE's march on VC

Assessing SoftBank's Vision Funds

You Might Also Like

So, about my last email

Witness the AI power for yourself: Join our training LIVE!

Jons Growth Journal Issue #3 - why I'm avoiding short form content, side hustle updates, YouTube Channnel

Alternative to Google Traffic?

Digiday's annual guide to ad-supported streaming services, from the top platforms to marketing spend

♦️ Why your brand needs an enemy to grow faster (and how to choose one)

🕝 24hr trading on the NYSE?

Tomorrow is the last chance to recognize your company's rising leaders

The future is retail media

Take a peek into the marketers’ tech stack, make it easy for customers to find your emails, and more